How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement

被引：2

作者：

Naoe, Tomoki ^{[1
]}

机构：

[1] Natl Hosp Org Nagoya Med Ctr, Nagoya, Aichi, Japan

来源：

NAGOYA JOURNAL OF MEDICAL SCIENCE | 2020年 / 82卷 / 02期

关键词：

elderly patients; acute myeloid leukemia; chemotherapy; molecule-targeted drug; prognosis; ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; LOW-DOSE CYTARABINE; CONVENTIONAL CARE REGIMENS; OLDER PATIENTS; ARSENIC TRIOXIDE; PLUS CYTARABINE; PHASE-2; TRIAL; OPEN-LABEL; AML;

D O I：

10.18999/nagjms.82.2.151

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Among elderly patients with acute myeloid leukemia (AML), especially those who are unfit for intensive chemotherapy, a policy of reduced-intensity chemotherapy or conservative observation has been chosen, resulting in unmet medical needs. Clinical trials using anticancer drugs including antimetabolites or drugs targeted to cell cycle-related molecules failed to show superiority over conventional treatments. Recently, drugs targeted to Bcl-2, SMO, FLT3, and IDH1/2 have been shown to prolong overall survival alone or in combination with reduced-intensity chemotherapy. These treatments are likely to reshape the therapeutic landscape of AML, which will be personalized for individual patients based on leukemia genetics.

引用

页码：151 / 160

页数：10

共 56 条

[1] Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab [J].

Abaza, Yasmin ;

Kantarjian, Hagop ;

Garcia-Manero, Guillermo ;

Estey, Elihu ;

Borthakur, Gautam ;

Jabbour, Elias ;

Faderl, Stefan ;

O'Brien, Susan ;

Wierda, William ;

Pierce, Sherry ;

Brandt, Mark ;

Mccue, Deborah ;

Luthra, Rajyalakshmi ;

Patel, Keyur ;

Kornblau, Steven ;

Kadia, Tapan ;

Daver, Naval ;

DiNardo, Courtney ;

Jain, Nitin ;

Verstovsek, Srdan ;

Ferrajoli, Alessandra ;

Andreeff, Michael ;

Konopleva, Marina ;

Estrov, Zeev ;

Foudray, Maria ;

Mccue, David ;

Cortes, Jorge ;

Ravandi, Farhad .

BLOOD, 2017, 129 (10) :1275-1283

[2] Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience [J].

Ades, L ;

Chevret, S ;

De Botton, S ;

Thomas, X ;

Dombret, H ;

Beve, B ;

Sanz, M ;

Guerci, A ;

Miguel, JS ;

dela Serna, J ;

Garo, C ;

Stoppa, AM ;

Reman, O ;

Stamatoulas, A ;

Fey, M ;

Cahn, JY ;

Sotto, JJ ;

Bourhis, JH ;

Parry, A ;

Chomienne, C ;

Degos, L ;

Fenaux, P .

LEUKEMIA, 2005, 19 (02) :230-233

[3]

[Anonymous], CANC STAT FACTS LEUK

[4] Improved outcome for AML patients over the years 2000-2014 [J].

Bertoli, Sarah ;

Tavitian, Suzanne ;

Huynh, Anne ;

Borel, Cecile ;

Guenounou, Sarah ;

Luquet, Isabelle ;

Delabesse, Eric ;

Sarry, Audrey ;

Laurent, Guy ;

Attal, Michel ;

Huguet, Francoise ;

Berard, Emilie ;

Recher, Christian .

BLOOD CANCER JOURNAL, 2017, 7

[5] Approvals in 2018: a histology-agnostic new molecular entity, novel end points and real-time review [J].

Blumenthal, Gideon M. ;

Pazdur, Richard .

NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (03) :139-141

[6]

Brandwein JM, 2017, AM J BLOOD RES, V7, P30

[7] A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment [J].

Burnett, Alan K. ;

Milligan, Donald ;

Prentice, Archie G. ;

Goldstone, Anthony H. ;

McMullin, Mary F. ;

Hills, Robert K. ;

Wheatley, Keith .

CANCER, 2007, 109 (06) :1114-1124

[8] Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome [J].

Cortes, Jorge E. ;

Heidel, Florian H. ;

Hellmann, Andrzej ;

Fiedler, Walter ;

Smith, B. Douglas ;

Robak, Tadeusz ;

Montesinos, Pau ;

Pollyea, Daniel A. ;

DesJardins, Pierre ;

Ottmann, Oliver ;

Ma, Weidong Wendy ;

Shaik, M. Naveed ;

Laird, A. Douglas ;

Zeremski, Mirjana ;

O'Connell, Ashleigh ;

Chan, Geoffrey ;

Heuser, Michael .

LEUKEMIA, 2019, 33 (02) :379-389

[9] Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure [J].

de The, Hugues ;

Pandolfi, Pier Paolo ;

Chen, Zhu .

CANCER CELL, 2017, 32 (05) :552-560

[10] Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML [J].

DiNardo, C. D. ;

Stein, E. M. ;

de Botton, S. ;

Roboz, G. J. ;

Altman, J. K. ;

Mims, A. S. ;

Swords, R. ;

Collins, R. H. ;

Mannis, G. N. ;

Pollyea, D. A. ;

Donnellan, W. ;

Fathi, A. T. ;

Pigneux, A. ;

Erba, H. P. ;

Prince, G. T. ;

Stein, A. S. ;

Uy, G. L. ;

Foran, J. M. ;

Traer, E. ;

Stuart, R. K. ;

Arellano, M. L. ;

Slack, J. L. ;

Sekeres, M. A. ;

Willekens, C. ;

Choe, S. ;

Wang, H. ;

Zhang, V. ;

Yen, K. E. ;

Kapsalis, S. M. ;

Yang, H. ;

Dai, D. ;

Fan, B. ;

Goldwasser, M. ;

Liu, H. ;

Agresta, S. ;

Wu, B. ;

Attar, E. C. ;

Tallman, M. S. ;

Stone, R. M. ;

Kantarjian, H. M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (25) :2386-2398

← 1 2 3 4 5 6 →